Multimedia

Jan. 19, 2018
References
  1. Hoffman R, et al. Hodgkin lymphoma: Clinical manifestations, staging, and therapy. In: Hematology: Basic Principles and Practice. 7th ed. Philadelphia, Pa.: Elsevier; 2018. https://www.clinicalkey.com. Accessed Oct. 16, 2017.
  2. The lymphoma guide: Information for patients and caregivers. Leukemia & Lymphoma Society. http://www.lls.org/resource-center/download-or-order-free-publications?language=English&category=Lymphoma. Accessed July 18, 2017.
  3. Adult Hodgkin lymphoma treatment (PDQ). National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Accessed July 18, 2017.
  4. Distress management. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed July 18, 2017.
  5. Hodgkin lymphoma. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed July 18, 2017.
  6. Lymphoma SPOREs. National Cancer Institute. http://trp.cancer.gov/spores/lymphoma.htm. Accessed July 18, 2017.
  7. Maurer MJ, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology. 2014;32:1066.
  8. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 26, 2017.
  9. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017;35:2008.
  10. Ansell SM, et al. Pd-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine. 2015;372:311.
  11. Johnston PB, et al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): Safety and efficacy results of a phase 1 and feasibility trial. The Lancet Haematology. 2016;3:e309. http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30040-0/abstract. Accessed July 24, 2017.
  12. Mayo Clinic first in U.S. to offer genetic test for lymphoma. Forefront. 2017;6. http://www.mayo.edu/research/forefront/mayo-clinic-first-us-offer-genetic-test-lymphoma. Accessed July 24, 2017.
  13. What you need to know about Hodgkin lymphoma. National Cancer Institute. https://www.cancer.gov/publications/patient-education/wyntk-hodgkin. Accessed June 12, 2017.
  14. Thompson CA (expert opinion). Mayo Clinic, Rochester, Minn. Oct. 5, 2017.
  15. Nowakowski GS, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase II study. Journal of Clinical Oncology. 2015;33:251.
  16. AskMayoExpert. Hodgkin lymphoma. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2017.
  17. Barbara Woodward Lips Patient Education Center. Hodgkin lymphoma. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2006.
  18. Common side effects of radiation therapy. American Cancer Society. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/coping.html. Accessed July 27, 2017.